- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Medicus Pharma plant Webcast zu Studienergebnissen bei Basalzellkarzinom | 1 | Investing.com Deutsch | ||
| Mo | Medicus Pharma schedules webcast on basal cell carcinoma study | 1 | Investing.com | ||
| Mo | Medicus Pharma Ltd: Medicus Pharma Announces SkinJect Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 | 109 | GlobeNewswire (Europe) | Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16... ► Artikel lesen | |
| 10.03. | Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum | 342 | ACCESS Newswire | Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy PHILADELPHIA, PA / ACCESS Newswire / March 10, 2026 / Medicus... ► Artikel lesen | |
| 09.03. | Medicus Pharma Ltd: Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset | 221 | GlobeNewswire (Europe) | PHILADELPHIA, March 09, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 06.03. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.03. | Medicus Pharma Reports Phase 2 Results For D-MNA Skin Cancer Treatment, Stock Down In Pre-Market | 1 | RTTNews | ||
| 05.03. | Medicus Pharma Stock Swings After Skin Cancer Treatment Results | 2 | Benzinga.com | ||
| 05.03. | Medicus Pharma Ltd: Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200µg Cohort | 809 | GlobeNewswire (Europe) | PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 28.02. | New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd., CitroTech, Vivos Therapeutics, Inc., and Virtuix Holdings on Bloomberg Television Tonight at 6:30 PM EST | 570 | ACCESS Newswire | The Show Will Also Air Across Latin America and MENA 1230 pm local time. NEW YORK CITY, NEW YORK / ACCESS Newswire / February 28, 2026 / New to The Street will broadcast nationally tonight at 6:30 PM... ► Artikel lesen | |
| 12.02. | Medicus Pharma Ltd: Medicus Pharma on Bloomberg World | 634 | ACCESS Newswire | Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus"... ► Artikel lesen | |
| 10.02. | New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd. | 374 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / February 10, 2026 / New to The Street, the nationally syndicated, long-form television and digital media platform, today announced it has signed a six-part media... ► Artikel lesen | |
| 10.02. | FDA clears Medicus Pharma's prostate cancer drug for phase 2b trial | 4 | Investing.com | ||
| 10.02. | Medicus Pharma Ltd: Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk | 2.654 | GlobeNewswire (Europe) | PHILADELPHIA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical... ► Artikel lesen | |
| 23.01. | Medicus Pharma Ltd: Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony | 952 | ACCESS Newswire | PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing... ► Artikel lesen | |
| 22.01. | Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic and Development Profile | 1 | GlobeNewswire (USA) | ||
| 20.01. | Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 | 2 | GlobeNewswire (USA) | ||
| 05.01. | Medicus Pharma to present phase 2 data at Biotech Showcase 2026 | 2 | Investing.com | ||
| 05.01. | Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates | 2 | GlobeNewswire (USA) | ||
| 30.12.25 | Medicus Pharma startet "At-the-Market"-Eigenkapitalprogramm über bis zu 15,3 Mio. US-Dollar | 2 | Investing.com Deutsch |
1 2 3 4 Weiter >>
74 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,095 | -0,15 % | UBS stuft PFIZER INC auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Pfizer auf "Neutral" mit einem Kursziel von 25 US-Dollar belassen. Analyst Michael Yee verwies in einer am Dienstag vorliegenden... ► Artikel lesen | |
| GILEAD SCIENCES | 125,62 | -0,44 % | Dividendenbekanntmachungen (13.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIAN ASSET MANAGEMENT INC US10948W1036 0,1 USD 0,0868 EUR ALBEMARLE CORPORATION US0126531013 0,405 USD 0,3516 EUR ALEXANDRIA... ► Artikel lesen | |
| ELI LILLY | 856,40 | -0,24 % | Novo Nordisk und Eli Lilly: Der Konkurrenzkampf geht in die nächste Runde | Novo Nordisk hat die Distribution seiner Abnehmmedikamente über die Hims-Plattform angekündigt. Die Einigung beendet einen monatelangen Konflikt um Nachahmerpräparate und schafft neue Perspektiven für... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 409,00 | +1,01 % | Aktien New York Ausblick: Erholung verpufft - Biontech-Kurs bricht ein | NEW YORK (dpa-AFX) - Mit der Erholung der Kurse an den US-Börsen dürfte es am Dienstag schon wieder vorbei sein. Die Aussage von US-Präsident Donald Trump, wonach der Krieg im Nahen Osten "so gut wie... ► Artikel lesen | |
| EYEPOINT | 11,465 | 0,00 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| LIGAND PHARMACEUTICALS | 180,00 | -0,55 % | Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst | ||
| JAZZ PHARMACEUTICALS | 157,75 | -0,25 % | Jazz Pharmaceuticals Plc Q4 Profit Climbs | WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) released earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings totaled $203.45 million,... ► Artikel lesen | |
| UNITED THERAPEUTICS | 464,60 | +0,02 % | United Therapeutics Stock Surges 32% in 6 Months: Here's Why | ||
| OPKO HEALTH | 0,965 | -1,73 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results | MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces... ► Artikel lesen | |
| ROYALTY PHARMA | 40,220 | +0,40 % | Royalty Pharma plc: Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,820 | +2,87 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 62,06 | +0,52 % | BridgeBio Pharma, Inc.: BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 | - Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified... ► Artikel lesen | |
| TG THERAPEUTICS | 24,915 | +0,10 % | TG Therapeutics, Inc.: TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance | Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 8,100 | -1,82 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update | Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancerCRB-701 data for both indications is expected in mid-2026... ► Artikel lesen | |
| SOLIGENIX | 1,220 | -0,81 % | SOLIGENIX, INC.: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) | Study results support advancing SGX945 in this difficult-to-treat orphan disease
Results suggest potential durability of response for maintenance therapy
PRINCETON, N.J., Dec. 18... ► Artikel lesen |
Das Unternehmen MEDICUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,525 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.